Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cobitolimod - InDex Pharmaceuticals

Drug Profile

Cobitolimod - InDex Pharmaceuticals

Alternative Names: AEL; Antisense NF-KB-p65 oligonucleotide; Antisense oligonucleotide NF-KB-p65; Cobitolimod sodium - InDex Pharmaceuticals; DIMS-0150; IDX0150; Kappaproct; NF-ĸB(p65)AS

Latest Information Update: 24 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InDex Pharmaceuticals
  • Class Anti-inflammatories; Antiulcers; Oligodeoxyribonucleotides
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ulcerative colitis
  • Discontinued Brain oedema

Most Recent Events

  • 21 Nov 2023 InDex Pharmaceuticals terminates a phase III CONCLUDE trial in Ulcerative colitis (Treatment-experienced) in US, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Croatia, France, Georgia, Germany, Hungary, Israel, Italy, South Korea, Lithuania, Mexico, the Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Sweden, Turkey and may extends to Denmark, Canada and UK due to unlikely possibility to meet the primary endpoint (NCT04985968)
  • 20 Oct 2023 InDex Pharmaceuticals has patent protection for cobitolimod in in the treatment of inflammatory bowel disease in South Korea
  • 14 Oct 2023 Safety and pharmacokinetics data from a phase I/II trial in colonic inflammation presented at the (f31st United European Gastroenterology Week (UEG -2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top